{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T05:40:32Z","timestamp":1768801232422,"version":"3.49.0"},"reference-count":31,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T00:00:00Z","timestamp":1694995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Since EXTRA, a non-randomized phase II trial with 31 patients, explored the use of capecitabine, mitomycin and radiation therapy (RT) in the treatment of localized squamous cell carcinoma of the anal canal (SCCAC), this treatment has been considered as an acceptable alternative to infusional 5-FU. However, the differences in efficacy between capecitabine and 5-FU in chemoradiation therapy (CRT) with simultaneous integrated boost (SIB) radiation therapy (SIB-IMRT) for local SCCAC are not well documented. Patients included in this prospective monocentric cohort study were treated with SIB-RapidArc (a unique RT method treatment for all patients: identical technique, volume and constraints for at-risk organs), mitomycin C and 5-FU each day of RT for 7 weeks (group 1) or capecitabine each day of RT (group 2). Patients treated between July 2009 and August 2017 (group 1) and between November 2012 and April 2018 (group 2) for local SCCAC T2-4 classified as N, M0 or T, N1-3, M0 were included. Primary endpoints were progression-free survival (PFS) and acute toxicities. Results: One hundred forty-seven patients were included, 91 in group 1 and 56 in group 2. The two groups were statistically comparable in terms of sex, Eastern Cooperative Oncology Group Performance Status (ECOG PS) and TNM. With a median duration of follow-up of 53.5 months, the PFS rate at 3 years was 80% for group 1 and 75% for group 2 (p = 0.32). The 3-year colostomy-free survival rate was 92% for group 1 and 85% for group 2 (p = 0.11). The rate of patients with at least one grade 3 or higher acute toxicity was 35.5% in group 1 and 21.4% in group 2 (p = 0.10), with a trend of fewer acute toxicities with capecitabine. Conclusion: Capecitabine\/mitomycin in combination with SIB RapidArc radiation therapy for anal cancer seems as effective as 5-FU-based chemotherapy and is well tolerated with minimal toxicity.<\/jats:p>","DOI":"10.3390\/curroncol30090621","type":"journal-article","created":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T03:02:17Z","timestamp":1695092537000},"page":"8563-8574","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Capecitabine\/Mitomycin versus 5-Fluorouracil\/Mitomycin in Combination with Simultaneous Integrated Boost Intensity-Modulated Radiation Therapy for Anal Cancer"],"prefix":"10.3390","volume":"30","author":[{"given":"Laurent","family":"Mineur","sequence":"first","affiliation":[{"name":"Oncodigestive and Clinical Research Department, Sainte Catherine Institut du Cancer Avignon-Provence, 84918 Avignon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e9a","family":"Vazquez","sequence":"additional","affiliation":[{"name":"Oncodigestive and Clinical Research Department, Sainte Catherine Institut du Cancer Avignon-Provence, 84918 Avignon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Belkacemi","sequence":"additional","affiliation":[{"name":"Statistics Department, PRECIS, Nouvelles Technologies, Languedoc Mutualit\u00e9, 34000 Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e9mence","family":"Toullec","sequence":"additional","affiliation":[{"name":"Oncodigestive and Clinical Research Department, Sainte Catherine Institut du Cancer Avignon-Provence, 84918 Avignon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Newfel","family":"Bentaleb","sequence":"additional","affiliation":[{"name":"Oncodigestive and Clinical Research Department, Sainte Catherine Institut du Cancer Avignon-Provence, 84918 Avignon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rania","family":"Boustany","sequence":"additional","affiliation":[{"name":"Oncodigestive and Clinical Research Department, Sainte Catherine Institut du Cancer Avignon-Provence, 84918 Avignon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederi","family":"Plat","sequence":"additional","affiliation":[{"name":"Oncodigestive and Clinical Research Department, Sainte Catherine Institut du Cancer Avignon-Provence, 84918 Avignon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S1470-2045(12)70137-7","article-title":"Global burden of cancers attributable to infections in 2008: A review and synthetic analysis","volume":"13","author":"Ferlay","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.critrevonc.2018.12.007","article-title":"Cancer of the anal region","volume":"135","author":"Valvo","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/CEJ.0000000000000163","article-title":"Trends of incidence and survival in squamous-cell carcinoma of the anal canal in France: A population-based study","volume":"25","author":"Bouvier","year":"2016","journal-title":"Eur. J. Cancer. Prev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1002\/1097-0142(19830515)51:10<1826::AID-CNCR2820511012>3.0.CO;2-L","article-title":"Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal","volume":"51","author":"Nigro","year":"1983","journal-title":"Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"UKCCCR Anal Cancer Trial Working Party (1996). Epidermoid anal cancer: Results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. Lancet, 348, 1049\u20131054.","DOI":"10.1016\/S0140-6736(96)03409-5"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO.1996.14.9.2527","article-title":"Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: Results of a phase III randomized intergroup study","volume":"14","author":"Flam","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"ref_7","first-page":"3342","article-title":"Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: Results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastro","volume":"117","author":"Bartelink","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1470-2045(13)70086-X","article-title":"Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous cell carcinoma of the anus (ACT II): A randomised, phase 3, open-label, 2 \u00d7 2 factorial trial","volume":"14","author":"James","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1200\/JCO.2012.43.8085","article-title":"Long-term update of US GI intergroup RTOG 98-11 Phase III trial for anal carcinoma: Survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil\/mitomycin versus fluorouracil\/cisplatin","volume":"30","author":"Gunderson","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0360-3016(01)01510-3","article-title":"The impact of gap duration on local control of anal cancer treated by split-course radiotherapy and concomitant chemotherapy","volume":"50","author":"Weber","year":"2001","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1159\/000071200","article-title":"Impact of overall treatment time on local control of anal cancer treated with radiochemotherapy","volume":"65","author":"Graf","year":"2003","journal-title":"Oncology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1002\/cncr.25901","article-title":"Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal","volume":"117","author":"Bazan","year":"2011","journal-title":"Cancer"},{"key":"ref_13","first-page":"39","article-title":"Intensity-modulated radiation therapy vs. 3D conformal radiation therapy for squamous cell carcinoma of the anal canal","volume":"6","author":"Chuong","year":"2013","journal-title":"Gastrointest. Cancer Res."},{"key":"ref_14","first-page":"815","article-title":"Intensity-modulated radiation therapy for anal cancer: Toxicity versus outcomes","volume":"24","author":"Zagar","year":"2010","journal-title":"Oncology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/COC.0b013e31827e52a3","article-title":"Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer: Outcomes and toxicity","volume":"37","author":"Mitchell","year":"2014","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1259\/bjr\/22373346","article-title":"Volumetric modulated arc therapy: A review of current literature and clinical use in practice","volume":"84","author":"Teoh","year":"2011","journal-title":"Br. J. Radiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.rpor.2013.07.005","article-title":"Volumetric arc therapy with Rapid-Arc: An evaluation of treatment delivery efficiency","volume":"18","author":"Amendola","year":"2013","journal-title":"Rep. Pract. Oncol. Radiother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1053-4296(97)80025-2","article-title":"Irradiation plus 5-fluorouracil: Cellular mechanisms of action and treatment schedules","volume":"7","author":"Rich","year":"1997","journal-title":"Semin. Radiat. Oncol."},{"key":"ref_19","first-page":"2948","article-title":"X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts","volume":"5","author":"Sawada","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa073149","article-title":"Capecitabine and oxaliplatin for advanced eosophagogastric cancer","volume":"358","author":"Cunningham","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e15241","DOI":"10.1097\/MD.0000000000015241","article-title":"Capecitabine versus 5-5-fluorouracil in neoadjuvant chemoradiotherapy of locally advanced rectal cancer","volume":"98","author":"Zhu","year":"2019","journal-title":"Medicine"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijrobp.2007.12.012","article-title":"EXTRA\u2014A Multicenter Phase II Study of Chemoradiation Using a 5 Day per Week Oral Regimen of Capecitabine and Intravenous Mitomycin C in Anal Cancer","volume":"72","author":"Meadows","year":"2008","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e201","DOI":"10.1016\/j.ijrobp.2012.12.008","article-title":"Simultaneous integrated boost\u2013intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: A phase 1 study","volume":"85","author":"Deenen","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"665","DOI":"10.21037\/jgo.2016.06.04","article-title":"A comparison between 5-fluorouracil\/mitomycin and capecitabine\/mitomycin in combination with radiation for anal cancer","volume":"7","author":"Peixoto","year":"2016","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/1748-717X-9-124","article-title":"Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma","volume":"9","author":"Thind","year":"2014","journal-title":"Radiat. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s12029-015-9790-4","article-title":"Phase II Study of Capecitabine in Substitution of 5-FU in the Chemoradiotherapy Regimen for Patients with Localized Squamous Cell Carcinoma of the Anal Canal","volume":"47","author":"Oliveira","year":"2015","journal-title":"J. Gastrointest. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1038\/bjc.2014.467","article-title":"Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: An alternative treatment option","volume":"111","author":"Meulendijks","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"605","DOI":"10.21037\/jgo.2019.02.17","article-title":"Comparison of definitive chemoradiation with 5-fluorouracil versus capecitabine in anal cancer","volume":"10","author":"Pumpalova","year":"2019","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1200\/JCO.2005.04.9544","article-title":"Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144","volume":"24","author":"Smalley","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1200\/JCO.1997.15.1.110","article-title":"Patient preferences for oral versus intravenous palliative chemotherapy","volume":"15","author":"Liu","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.ijrobp.2017.03.022","article-title":"Capecitabine with mitomycin reduces acute hematological toxicity and treatment delays in patients undergoing definitive chemoradiation using Intensity Modulated Radiation Therapy fot Anal Cancer","volume":"98","author":"Goodman","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/9\/621\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:53:08Z","timestamp":1760129588000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/9\/621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,18]]},"references-count":31,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["curroncol30090621"],"URL":"https:\/\/doi.org\/10.3390\/curroncol30090621","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,18]]}}}